Novartis Sticks To 2018 Growth Target, Lifts Alcon Outlook

Novartis now expects Alcon’s full-year sales to rise by a low single-digit percentage rate, having previously forecast revenue to remain stable or a low-single digit percentage rise.
Novartis on Tuesday reiterated its forecast that sales would start growing again in 2018 and slightly lifted the full-year outlook for its Alcon eyecare division, as sales of surgical equipment finally ended a string of declines.
Sales fell 2 percent to $12.242 billion, hurt by declining revenue from blood cancer drug Gleevec and U.S. price pressure at the company’s Sandoz generics business.
Core net income fell 2 percent to $2.87 billion, the Swiss drugmaker said in a statement, but beat the average analyst forecast of $2.668 billion in a Reuters poll.

Read more on: